Nuchev wins Shanghai arbitration against Nouvlait, awarded ~RMB9.1 million
Nuchev Limited (ASX: NUC) has received a final arbitration award from the Shanghai Arbitration Commission, dated 4 September 2026, resolving a long-running dispute against Hulun Buir Nouvlait Dairy Co., Ltd (Nouvlait). The Tribunal found in Nuchev’s favour, determining that Nouvlait breached its contractual obligations and that the actions of Nouvlait’s representative were binding on the company.
The dispute originated in 2021 as part of Nuchev’s former China infant formula registration strategy, under which Nuchev paid an advance of RMB5.0 million to Nouvlait. Nuchev’s PRC legal advisers currently estimate the total amount payable under the award, including interest to date, at approximately RMB9.1 million (approximately A$1.9 million at current exchange rates). The Australian dollar equivalent is indicative only and will move with exchange rates. The Tribunal did not uphold Nuchev’s separate claim for anticipated profits.
When big ASX news breaks, our subscribers know first
Breaking down the arbitration award
The Tribunal ordered Nouvlait to pay Nuchev across several components. Fixed amounts total approximately RMB8.37 million, plus accrued and continuing interest on the RMB5.0 million advance.
| Award Component | Amount (RMB) |
|---|---|
| Repayment of original advance | 5,000,000 |
| Actual losses | 2,890,000 |
| Legal costs | 267,215 |
| Appraisal costs | 23,600 |
| Arbitration costs | 190,735 |
| Total fixed amounts | ~8,370,000 |
| Interest on RMB5.0M (from 22 December 2021) | Accruing at one-year Loan Prime Rate |
What is commercial arbitration — and why does enforcement matter?
A commercial arbitration award is a binding legal determination issued by an independent tribunal, outside of court proceedings. When both parties agree to arbitration, the outcome carries legal force — but it is not automatically enforced like a court order.
In cross-border disputes, winning an arbitration award and actually recovering funds are two distinct steps. For an Australian claimant seeking payment from a China-based counterparty, the award must be enforced through the relevant foreign court system. This process can be slower and less predictable than enforcing a domestic judgement, depending on the assets available, the counterparty’s willingness to comply, and the legal avenues available to challenge or delay enforcement.
This distinction is the central investor-relevant consideration for Nuchev’s award. The legal outcome is decided; the financial outcome remains uncertain.
Enforcement uncertainty and financial impact
Recovery is not guaranteed
No payment has been received from Nouvlait. Nuchev’s PRC legal advisers do not currently expect Nouvlait to pay voluntarily, and court enforcement is anticipated. Nouvlait was required to pay the award within 10 days of the award date of 4 September 2026, though shareholders should not assume the approximately RMB9.1 million currently payable will be recovered in full or within that 10-day window.
Nuchev is working with its PRC legal advisers to begin the enforcement process, which includes confirming what assets are available, Nuchev’s priority against those assets, and the likely timing and cost of recovery. The company is also taking advice on any rights available to Nouvlait to challenge, delay, or resist enforcement.
Financial position context
At 30 June 2026, the original Nouvlait deposit had a carrying value of A$150,000 in Nuchev’s financial statements, following impairment recognised in prior periods. No amount had been recognised for damages or other potential recoveries from the arbitration.
Any amount ultimately received will be net of performance-based adviser fees, enforcement and recovery costs, tax, and any costs of repatriating funds from China. For these reasons, Nuchev is not yet in a position to quantify the net amount it may ultimately receive. The company will update the market as the enforcement and recovery process progresses.
Nuchev’s liquidity position is supported by a shareholder-supported working capital facility of up to $6.0m from H&S Global Holdings, with $2.5m still undrawn and maturity extended to 31 March 2028, meaning any arbitration recovery would supplement, rather than substitute for, existing funding arrangements.
What this means for Nuchev shareholders
The arbitration award validates Nuchev’s legal position and creates a legitimate claim on an amount that is meaningful relative to the A$150,000 carrying value currently recorded on its books. The award states it is final and took legal effect from the date it was made.
Nuchev FY26 results show closing cash of just $2.1m alongside an EBITDA loss that widened 36.3% to $(4.6)m, context that makes the net recovery quantum from this arbitration award a meaningful variable in the company’s near-term financial picture.
Investors should, however, hold the positive result alongside several key uncertainties: the enforcement timeline through Chinese courts, the net recovery amount after adviser fees, enforcement costs, tax, and repatriation costs, and the movement of the A$ equivalent as exchange rates fluctuate.
Nuchev is an Australian nutrition, wellness and health-products business with a portfolio that includes Oli6®, BioPractica and Medicine Tree. Products are sold through grocery, pharmacy, practitioner, digital and selected international channels, including China Cross-Border E-Commerce. The company has committed to providing market updates as its recovery position becomes clearer.
Don’t Miss the Next Consumer Sector Update
Get FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements land. Click the “Free Alerts” button at StockWire X to start receiving alerts today.